Todd Verdoorn compensation by year
DiaMedica Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2017 | FY2018 |
|---|---|---|
| Salary | $200,000 | $221,667 |
| Bonus | $40,000 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $98,670 | $156,848 |
| Non-equity incentive | $0 | $36,000 |
| Pension and deferred compensation | $0 | $0 |
| All other | $7,200 | $8,867 |
| Total | $345,870 | $423,382 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: DiaMedica Therapeutics Inc. DEF 14A filed April 8, 2019, accession 0001437749-19-006692, and prior-year filings.
How this page was built: the DiaMedica Therapeutics Inc. filed document, accession 0001437749-19-006692. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2019.
Equity holdings
unvested awards at FY2018 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 8,333 | — | $5.20 |
| Option | 12,500 | — | $6.40 |
| Option | 18,146 | — | $11.20 |
Per the Outstanding Equity Awards at Fiscal Year-End table in DiaMedica Therapeutics Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.
DiaMedica Therapeutics’s named executive officers, FY2018
as the company reported each| Named executive officer | Role | FY2018 total |
|---|---|---|
| Rick Pauls | President and Chief Executive Officer | $733,707 |
| Scott Kellen | Chief Financial Officer and Secretary | $642,921 |
| Todd Verdoorn · this page | Chief Scientific Officer | $423,382 |
The full DiaMedica Therapeutics compensation record
free company briefThis page is one person within DiaMedica Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the DiaMedica Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are DiaMedica Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.